α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: An inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2657-2668

  Ghosh, Sutapa ^a,b   Zheng, Yaguo ^a,b   Jun, Xiao ^a,b   Narla, Rama Krishna ^b   Mahajan, Sandeep ^b   Navara, Christopher ^a,b   Mao, Chen ^b   Sudbeck, Elise A ^b   Uckun, Fatih M ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYANO BETA HYDROXY BETA METHYL N [4 (TRIFLUOROMETHOXY)PHENYL] PROPENAMIDE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LEFLUNOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; ISOXAZOLES; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; NITRILES; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0031785254     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Wood, W. C. Progress from clinical cancer. Cancer (Phila.), 74: 2606-2609, 1994.
2. Hortobagyi, G. N. Chemotherapy of breast cancer: a historical perspective. Semin. Oncol., 24: S17-1-S17-4, 1997.
3. Norton, L. Conceptual basis for advances in the systemic drug therapy of breast cancer. Semin. Oncol., 24: S11-2-S11-12, 1997.
4. Drukker, B. H. Breast disease: a primer on diagnosis and management. Int. J. Fertil. Womens Med., 42: 278-287, 1997.
5. Gordon, A. The increasing efficacy of breast cancer treatment. Clin. Oncol. R. Coll. Radiol., 9: 338-342, 1997.
6. Somlo, G., Doroshow, J. H., Forman, S. H., Leong, L. A., Margolin, K. A., Morgan, R. J., Jr., Raschoko, J. W., Akkman, S. A., Ahn, C., and Nagasawa, S. High-dose doxorubicin, etoposide and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 1678-1665, 1994.
7. Hortobagyi, G. N. Paclitaxel-based combination chemotherapy for breast cancer. Oncol. Huntingt., 11 (3 Suppl. 2): 29-37, 1997.
8. Holmes, F. A. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin. Oncol., 23 (5 Suppl. 11): 46-56, 1996.
9. Bonadonna, G., Zambetti, M., and Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J. Am. Med. Assoc., 273: 542-547, 1995.
10. Ingle, J. N., Foley, J. F., Mailliard, J. A., Krook, J. E., Hartman, L. C., Jung, S. H., Veeder, M. H., Gesme, D. H. J., Hatfield, A. K., and Goldberg, R. M. Randomized trial of cyclophosphamide, methoxate, and 5-fluorouracil with or without without estrogenic recruitment in women with metastatic breast cancer. Cancer (Phila.). 73: 2337-2343, 1994.
11. Abrams, J. S., Moore, T. D., and Friedman, M. New chemotherapeutic agents for breast cancer. Cancer (Phila.), 84: 1164-1176, 1994.
12. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
13. George-Nascimento, C., Gyenes, A., Halloran, S. M., Merryweather, J., Valenzuela, P., Steimer, K. S., Masiarz, F. R., and Randolph, A. Characterization of recombinant human epidermal growth factor produced in yeast. Biochemistry, 27: 797-802, 1988.
14. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev., 12: 255-274, 1993.
15. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.) Biologic Therapy of Cancer: Principles & Practice, pp. 607-623. Philadelphia, PA: J. B. Lippincott Co., 1995.
16. Toi, M., Osaki, A., Yamada, H., and Toge, T. Epidermal growth factor receptor expression as a prosnostic indicator in breast cancer. Eur. J. Cancer, 27: 977-980, 1991.
17. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
18. Uckun, F. M., Narla, R. K., Jun, X., Zeren, T., Venkatachalam, T., Waddick, K., Rostostev, A., and Myers, D. E. Cytotoxic activity of EGF-Genistein against human breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.
19. Parnham, M. J. Leflunomide: a potential new disease modifying anti-rheumatic drug. Exp. Opin. Invest. Drugs, 4: 777-779, 1995.
20. Xu, X., Williams, J. W., Gong, H., Finnegan, A., and Chong, A. S. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem. Pharmacol., 52: 527-534, 1996.
21. Xu, X., Williams, J. W., Bremer, E. G., Finnegan, A., and Chong, A. S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem., 270: 12398-12403, 1995.
22. Bertolini, G., Aquino, M., Biffi, M., d'Atri, G., Di Pierro, F., Ferrario, F., Mascagni, P., Somenzi, F., Zaliani, A., and Leoni, F. A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug. J. Med. Chem., 40: 2011-2016, 1997.
23. Mattar, T., Kochhar, K., Bartlett, R., Bremer, E. G., and Finnegan, A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett., 334: 161-164, 1993.
24. Sicheri, F., Moarefi. I., and Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature (Lond.), 385: 602-609, 1997.
25. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (Washington DC), 276: 955-960, 1997.
26. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J., 16: 5572-5581, 1997.
27. Zheng, J., Trafny, E. A., Knighton, D. R., Xuong, N-H., Taylor, S. S., Ten Eyck, L. F., and Sowadski, J. M. 2.2Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Cryst., D49: 362-365, 1993.
28. Sack, J. S. CHAIN-a cristallographic modeling program. J. Mol. Graphics, 6: 244-245, 1988.
29. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des., 8: 243-256, 1994.
30. Kuo, E. A., Hambleton, P. T., Kay, D. P., Evans, P. L., Matharu, S. S., Little, E., McDowall, N., Jones, C. B., Hedgecock, C. J., Yea, C. M., Chan, A. W., Hairsine, P. W., Ager, I. R., Tully, W. R., Williamson, R. A., and Westwood, R. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3′-methyl-4′-(trifluoromethyl) phenyl] propenamide and related compounds. J. Med. Chem., 39: 4608-4621, 1996.
31. Sjogren, E. R., Rider, M. A., Nelson, P. H., Bingham, S., Poulton, A. L., Emanuel, M. A., and Komuniecki, R. Synthesis and biological activity of a series of diaryl-substituted α-cyano-β-hydroxypropenamides, a new class of antihelmintic agents. J. Med. Chem., 34: 3295-3301, 1991.
32. Narla, R. K., Liu, X. P., Myers, D. E., and Uckun, F. M. 4-(3′-Bromo-4′ hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154): a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin. Cancer Res., 4: 1405-1414, 1998.
33. Uckun, F. M., Waddick, K. G., Mahajan, S., Jun, X., Takata, M., Bolen, J., and Kurosaki, T. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science (Washingotn DC), 22: 1096-1100, 1996.
34. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
35. Heeg, K., Reimann, J., Kabelitz, D., Hardt, C., and Wagner, H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J. Immunol. Methods, 77; 237-246, 1985.
36. Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., and Ferrin, T. E. A geometric approach to macromolecular-ligand interactions. J. Mol. Biol., 161: 269-288, 1982.
37. Palmer, B. D., Fry, D. W., Nelson, J. M., Showalter, H. D., and Denny, W. A. Soluble analogs of pyrrolo-and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation and modeling of the mode of binding. J. Med. Chem., 40: 1519-1529, 1997.
38. Mohammadi, M., Schlessinger, J., and Hubbard, S. R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86: 577-587, 1996.
39. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science (Washington DC), 221: 709-713, 1983.